# colorectal cancer - gpt-5.6-luna

- Benchmark system: E2seq + Agent RAG
- Repeat: 3
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 62357
- Completion tokens: 26860
- Reasoning tokens: 0
- Total tokens: 89217
- API requests reported: 5
- Elapsed seconds: 220.761
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1848.064
- Question handoff seconds: 1861.273
- Final benchmark system: E2seq; file rank 2/5; original repeat 3; model vendor: OpenAI

---
## Data-quality and statistical context

This is a survival analysis of colorectal tumor tissue, with **100 unique genes and 209 retained gene/probe rows**. The statistical ledger reports **54 risk-associated genes (HR > 1)** and **46 protective-associated genes (HR < 1)**. Eight genes have **FDR ≤ 0.01**, and 71 have **FDR ≤ 0.05**; however, all 100 have nominal P ≤ 0.05, so the tail of the list contains many findings that do not remain significant after FDR correction.

Several genes have duplicate probe or grouped rows, and **DCBLD2, LOC101928747|RBMX|SNORD61, and BCL2L14 have direction conflicts across retained rows**. Their representative directions should therefore be treated cautiously. The supplied GO/KEGG and STRING results were generated previously and are contextual annotations, not new statistical tests; in particular, the reported pathway recurrence is **not formal pathway enrichment or independent validation**.

## 1. Overall biological interpretation

The strongest survival-associated pattern is a contrast between:

- a **risk-associated mesenchymal, adhesion, extracellular-interface, and signaling phenotype**, represented by INHBB, DCBLD2, TPM4, PTPN14, ITGBL1, ABL2, NT5E, and MSLN; and
- a **protective differentiated epithelial and metabolic phenotype**, represented by CDX2, MYO5B, LGAL​S4, GLYCTK, CS, NDUFA9, ATP23, and related mitochondrial or metabolic genes.

This pattern is biologically compatible with colorectal tumors in which poorer OS is associated with a more invasive or stromal-interacting state, whereas better OS is associated with retained intestinal epithelial identity and oxidative/metabolic functions. The dataset supports these as **prognostic associations**, not causal mechanisms. It does not establish that any listed gene drives survival, nor does it provide an independent-cohort statistic.

The most statistically secure individual signals are INHBB (**HR=1.4332849, P=1.9993823e-08, FDR=0.0010931622**), SCARA3 (**HR=1.3772977, P=8.9051939e-08, FDR=0.0024344574**), MIR31HG (**HR=1.3093772, P=4.2083644e-07, FDR=0.0066355753**), ATP23 (**HR=0.68848836, P=4.854559e-07, FDR=0.0066355753**), ZEB1-AS1 (**HR=1.3719515, P=9.8292748e-07, FDR=0.0086471166**), DCBLD2 (**HR=1.4080371, P=9.860365e-07, FDR=0.0086471166**, but with row-level direction conflict), and NDUFA9 (**HR=0.68863259, P=1.107084e-06, FDR=0.0086471166**).

## 2. Core biological programs

### Program 1: Mesenchymal–extracellular-interface and cell-motility phenotype

- **Direction:** Predominantly risk-associated.
- **Supporting genes:** INHBB, DCBLD2, TPM4, PTPN14, ITGBL1, ABL2, NPR3, NT5E, MSLN, SCEL, ADAMTS18, and several long noncoding transcripts including MIR31HG and ZEB1-AS1.
- **Relevant standardized pathway concepts:** Reactome **Extracellular matrix organization** and **Cell–cell/cell–matrix adhesion**; Hallmark **Epithelial–Mesenchymal Transition** is a plausible interpretive framework, but it was not formally tested in the supplied analysis.
- **Interpretation:** Multiple risk-associated genes encode or regulate cell-surface, cytoskeletal, extracellular-matrix, or adhesion-related functions. TPM4 and ABL2 are compatible with cytoskeletal and motility signaling; ITGBL1, DCBLD2, and ADAMTS18 suggest extracellular-interface biology; NT5E and MSLN are consistent with tumor–microenvironment interaction. Their collective direction is more informative than any one gene alone.
- **Evidence strength:** **Supported hypothesis** from the uploaded survival associations, with contextual support from pathway annotations and network records.
- **Limitations:** No formal gene-set enrichment statistic, epithelial–mesenchymal score, tumor-purity adjustment, or independent-cohort survival statistic was supplied. DCBLD2 has direction-conflicting rows, and some lncRNA/probe annotations may be uncertain. Stromal abundance or tumor purity could produce this pattern without tumor-cell-intrinsic EMT.

### Program 2: Retained intestinal epithelial differentiation and epithelial organization

- **Direction:** Predominantly protective-associated.
- **Supporting genes:** CDX2 (**HR=0.74776163, FDR=0.035501926**), CDX1 (**HR=0.78085163, FDR=0.05734561**), MYO5B (**HR=0.74832371, FDR=0.028227398**), LGALS4 (**HR=0.77119484, FDR=0.051227162**), and possibly CCL15 (**HR=0.75282151, FDR=0.035501926**) in a broader epithelial/microenvironment context.
- **Relevant standardized pathway concepts:** GO **intestinal epithelial cell differentiation**, **epithelial cell differentiation**, and **cell–cell junction organization**. These pathway labels are interpretive mappings rather than results of a new enrichment calculation.
- **Interpretation:** CDX1/CDX2, MYO5B, and LGALS4 form a coherent intestinal epithelial identity signal. Reduced CDX2-associated expression is biologically compatible with loss of differentiated epithelial characteristics in aggressive colorectal tumors. The supplied literature record reports that CDX2 suppresses proliferation and tumor formation in colon cancer cells through Wnt/β-catenin-related mechanisms (PMID: **30631044**, https://pubmed.ncbi.nlm.nih.gov/30631044/). This literature supports plausibility but does not replicate the present cohort.
- **Evidence strength:** **Supported hypothesis**, strongest for the combined differentiation pattern; CDX2 itself has direct statistical support.
- **Limitations:** CDX1 and LGALS4 do not meet FDR ≤ 0.05 in the representative rows, and epithelial markers are strongly affected by tumor purity and normal-epithelium content. The data cannot establish that differentiation is causally protective.

### Program 3: Mitochondrial and central metabolic capacity

- **Direction:** Predominantly protective-associated.
- **Supporting genes:** ATP23 (**HR=0.68848836, FDR=0.0066355753**), NDUFA9 (**HR=0.68863259, FDR=0.0086471166**), GLYCTK (**HR=0.70929051, FDR=0.020341929**), MCCC2 (**HR=0.7389587, FDR=0.028227398**), CS (**HR=0.75447917, FDR=0.038754165**), ILVBL (**HR=0.72456474, FDR=0.032940997**), COA3 (**HR=0.74374187, FDR=0.043364769**), ATP5G1, ATP5B, OGDHL, and ACSS2.
- **Relevant standardized pathways:** Reactome **Fructose catabolism** and **respiratory electron transport**; KEGG **glyoxylate and dicarboxylate metabolism** was among the supplied recurrent annotations. GLYCTK is also annotated to glycine/serine/threonine and glycerolipid metabolism.
- **Interpretation:** The coordinated protective direction of mitochondrial respiratory, tricarboxylic-acid-cycle, amino-acid, and carbohydrate-metabolism genes suggests that preserved metabolic differentiation is associated with longer OS. The STRING context also reports network associations involving CS with ACSS2 and ILVBL, and COA3 with ILVBL/MT-CO1. These are network-level associations, not evidence that the genes form a causal metabolic complex.
- **Evidence strength:** **Supported hypothesis**, particularly because ATP23 and NDUFA9 are among the most significant protective genes and several additional metabolic genes show the same direction.
- **Limitations:** The pathway records do not demonstrate enrichment, and the apparent metabolic signal may reflect epithelial content, mitochondrial mass, nutritional state, stage, or treatment exposure. Metabolic gene expression alone cannot distinguish increased oxidative metabolism from altered cell composition.

### Program 4: Tumor–immune and purinergic microenvironment signaling

- **Direction:** Mixed but with several risk-associated interface genes.
- **Supporting genes:** NT5E (**HR=1.312982, FDR=0.039390717**), LGALS9 (**HR=0.75332171, FDR=0.042038752**), CCL15 (**HR=0.75282151, FDR=0.035501926**), TAPBPL (**HR=0.71101448, FDR=0.019210192**), and NPR3 (**HR=1.3501879, FDR=0.016424072**).
- **Relevant standardized pathway concepts:** GO **regulation of T-cell migration** and purine/purinergic extracellular signaling; these were among the supplied batch annotations.
- **Interpretation:** NT5E is risk-associated and is biologically relevant to extracellular adenosine production and immune suppression. A supplied literature record describes CD73/NT5E as a cancer prognostic and immunotherapy biomarker across multiple cancer types (PMID: **36480312**, https://pubmed.ncbi.nlm.nih.gov/36480312/). However, LGALS9, CCL15, and TAPBPL are protective-associated in this dataset, so the immune interpretation is not unidirectional. This may indicate distinct immune states, tumor-cell versus immune-cell expression, or confounding by composition rather than a single immunosuppressive program.
- **Evidence strength:** **Exploratory to supported hypothesis**, with the clearest evidence for NT5E as a risk-associated biomarker candidate.
- **Limitations:** No immune deconvolution, cell-type-resolved expression, MSI status, immunotherapy exposure, or immune-cell functional assay was supplied. Literature on NT5E is not independent statistical replication of this cohort.

### Program 5: Cytoskeletal, centrosomal, and intracellular trafficking features

- **Direction:** Predominantly risk-associated for selected structural genes, although the program is heterogeneous.
- **Supporting genes:** NIN (**HR=1.345184, FDR=0.028227398**), MAP1B (**HR=1.3274716, FDR=0.047203854**), TPM4 (**HR=1.3635104, FDR=0.0089096897**), LRRC8A (**HR=1.3763533, FDR=0.025013259**), ABL2, GJB6, and protective-associated trafficking/epithelial genes such as MYO5B and RAB11FIP4.
- **Relevant standardized pathway concepts:** GO **microtubule anchoring at the microtubule organizing center** and **vesicle-mediated transport**.
- **Interpretation:** NIN, MAP1B, TPM4, and ABL2 collectively suggest cytoskeletal organization, cell polarity, or motility-related biology. In contrast, MYO5B and RAB11FIP4 are protective-associated and may reflect preserved epithelial trafficking. Thus, the most defensible interpretation is not “global cytoskeletal activation,” but a possible shift from organized epithelial trafficking toward invasive or structurally altered tumor states.
- **Evidence strength:** **Exploratory hypothesis**, supported by several concordant HRs and the supplied GO annotation.
- **Limitations:** The genes do not define a single validated complex, and the supplied STRING relationships are insufficient to infer direct physical interaction. The signal may overlap substantially with the mesenchymal/adhesion program.

## 3. Key genes and interaction modules

1. **INHBB** — Risk-associated, **HR=1.4332849, FDR=0.0010931622**. It is the strongest risk signal and is compatible with a TGF-β-family/stromal signaling hypothesis. The supplied Europe PMC record specifically reports high INHBB expression in colorectal cancer as associated with poor prognosis and malignant phenotypes (Europe PMC **41992239**, https://europepmc.org/article/MED/41992239). This is literature concordance, not independent statistical validation. Proposed relationships to DCBLD2, ITGBL1, or NT5E are **indirect or pathway-level**, not demonstrated direct interactions.

2. **ATP23** — Protective-associated, **HR=0.68848836, FDR=0.0066355753**. It supports the mitochondrial program and may mark preserved respiratory function. The supplied literature record describes genetic interaction of prohibitins with ATP23 (PMID: **17135288**), but that does not establish a direct ATP23 interaction with the other protective genes in this dataset.

3. **NDUFA9** — Protective-associated, **HR=0.68863259, FDR=0.0086471166**. It is a high-confidence marker of the protective mitochondrial phenotype. Its relationship with ATP23, COA3, and ATP5 genes is best described as **respiratory-chain or mitochondrial pathway co-membership**, not direct physical interaction based on the supplied evidence.

4. **SCARA3** — Risk-associated, **HR=1.3772977, FDR=0.0024344574**. It is among the strongest risk markers but does not, from the supplied records, define a coherent mechanism by itself. Its relationship to INHBB or DCBLD2 should be considered **putative co-expression or shared tumor-state association** unless experimentally demonstrated.

5. **DCBLD2** — Representative risk-associated, **HR=1.4080371, FDR=0.0086471166**, but flagged for direction conflict across rows. It is a candidate extracellular-interface marker, but probe-level concordance should be resolved before mechanistic prioritization. Relationships with ITGBL1 and PTPN14 are **cell-surface/adhesion pathway co-membership or indirect association**, not confirmed physical interaction.

6. **CDX2** — Protective-associated, **HR=0.74776163, FDR=0.035501926**. It anchors the intestinal differentiation interpretation and is supported by colon-cancer literature (PMID: **30631044**). Its relationship with CDX1 and LGALS4 is **co-expression and epithelial identity co-membership**; the supplied data do not establish direct regulation among these genes.

7. **GLYCTK–CS–ILVBL metabolic module** — GLYCTK (**HR=0.70929051, FDR=0.020341929**), CS (**HR=0.75447917, FDR=0.038754165**), and ILVBL (**HR=0.72456474, FDR=0.032940997**) are all protective-associated. STRING reports associations involving CS with ACSS2 and ILVBL. These are **database network associations**, with the precise physical or functional relationship not established here; the module is more securely interpreted as **metabolic pathway co-membership**.

8. **TPM4–ABL2–NIN–MAP1B structural module** — TPM4 (**HR=1.3635104, FDR=0.0089096897**), ABL2 (**HR=1.3012167, FDR=0.027572137**), NIN (**HR=1.345184, FDR=0.028227398**), and MAP1B (**HR=1.3274716, FDR=0.047203854**) are risk-associated. The relationship is **cytoskeletal and centrosomal functional convergence**, not a demonstrated direct complex.

9. **NT5E** — Risk-associated, **HR=1.312982, FDR=0.039390717**. It is a candidate tumor–immune interface biomarker. Its relationship to LGALS9, CCL15, and TAPBPL is **microenvironment/pathway co-membership or indirect immunologic association**; the mixed directions argue against treating them as one uniformly activated immune module.

10. **MIR31HG/ZEB1-AS1** — Both are risk-associated: MIR31HG (**HR=1.3093772, FDR=0.0066355753**) and ZEB1-AS1 (**HR=1.3719515, FDR=0.0086471166**). They may reflect regulatory states associated with invasion or dedifferentiation, but no direct regulatory edge was supplied. Their relationship to protein-coding genes is therefore an **unconfirmed regulatory hypothesis**, not established lncRNA-mediated control.

## 4. Validation priorities

### 1. INHBB-centered adverse prognostic mechanism  
**Classification:** Mechanistic hypothesis and biomarker.

- **Why prioritize it:** INHBB is the strongest risk-associated gene and has concordant colorectal-cancer literature.
- **Current evidence:** HR=1.4332849, P=1.9993823e-08, FDR=0.0010931622.
- **External evidence:** The supplied Europe PMC record links high INHBB expression with poor colorectal-cancer prognosis and malignant phenotypes (Europe PMC 41992239). This is supportive literature, not an independent cohort statistic.
- **Next step:** Validate INHBB protein and transcript levels in an independent, clinically annotated colorectal-cancer cohort, adjusting for stage, treatment, purity, and stromal fraction; then test perturbation in colorectal cancer organoids or cell models with invasion, survival, and pathway-readout assays.
- **Status:** **Supported hypothesis**, not established causality.

### 2. Epithelial differentiation versus invasive-state axis  
**Classification:** Mechanistic hypothesis and biomarker.

- **Why prioritize it:** CDX2, CDX1, MYO5B, and LGALS4 support a protective epithelial state, while TPM4, ITGBL1, ABL2, PTPN14, and related genes are risk-associated.
- **Current evidence:** CDX2 HR=0.74776163, FDR=0.035501926; MYO5B HR=0.74832371, FDR=0.028227398; ITGBL1 HR=1.299009, FDR=0.030609537; TPM4 HR=1.3635104, FDR=0.0089096897.
- **External evidence:** CDX2-related colorectal-cancer biology is supported by PMID 30631044.
- **Next step:** Construct and test a prespecified differentiation/invasion score in an independent cohort, followed by spatial transcriptomics or multiplex immunohistochemistry to determine whether the signal is tumor-cell intrinsic or reflects epithelial/stromal proportions.
- **Status:** **Supported hypothesis**.

### 3. Protective mitochondrial/metabolic state  
**Classification:** Mechanistic hypothesis and biomarker.

- **Why prioritize it:** ATP23 and NDUFA9 are among the most significant protective genes, with additional concordant metabolic genes.
- **Current evidence:** ATP23 HR=0.68848836, FDR=0.0066355753; NDUFA9 HR=0.68863259, FDR=0.0086471166; GLYCTK HR=0.70929051, FDR=0.020341929.
- **External evidence:** Reactome and MyGene annotations support mitochondrial and carbohydrate/serine-related functions; STRING supplies network associations involving CS, ACSS2, ILVBL, and COA3. These annotations are mechanistic context, not survival replication.
- **Next step:** Measure oxygen-consumption rate, mitochondrial mass, ATP production, and metabolite profiles in tumors or organoids stratified by the protective signature.
- **Status:** **Exploratory to supported hypothesis**.

### 4. NT5E-associated tumor–immune microenvironment  
**Classification:** Biomarker and mechanistic hypothesis.

- **Why prioritize it:** NT5E is risk-associated and has broad cancer-prognostic literature support, but the surrounding immune genes are directionally mixed.
- **Current evidence:** NT5E HR=1.312982, FDR=0.039390717; LGALS9, CCL15, and TAPBPL are protective-associated.
- **External evidence:** PMID 36480312 supports NT5E/CD73 as a cancer prognostic and immunotherapy-related biomarker, but does not establish effectiveness in this cohort or colorectal-cancer OS specifically.
- **Next step:** Perform cell-type-resolved measurement of NT5E, adenosine-pathway components, T-cell infiltration, and immune checkpoint status, with stratification by MSI and treatment exposure.
- **Status:** **Exploratory hypothesis** because of the mixed directions and absent cell-composition data.

### 5. Composition, purity, and clinical-confounding assessment  
**Classification:** Confounding or composition check.

- **Why prioritize it:** The contrast between epithelial/metabolic protective genes and stromal/interface risk genes could arise partly from tumor purity, epithelial content, fibroblasts, immune infiltration, stage, or treatment.
- **Current evidence:** The gene pattern is compatible with such confounding, but the supplied results contain no purity estimates, deconvolution, stage-adjusted model, or treatment covariates.
- **External evidence:** Tissue-expression and pathway annotations establish plausibility but do not resolve composition.
- **Next step:** Refit survival models with tumor purity, stage, age, sex, treatment, MSI, and molecular subtype; apply validated cell deconvolution and confirm representative proteins by spatial or multiplex assays.
- **Status:** This is an **essential validation requirement**, not a biological conclusion.

## 5. Evidence grounding and conflicts

- **Direct cohort evidence:** The HR, P value, FDR, and direction for each gene come only from the supplied table and ledger. These values should not be replaced by external annotations.
- **Pathway/ontology evidence:** The batch identified GO terms including regulation of phospholipase C activity, microtubule anchoring at the microtubule-organizing center, and regulation of T-cell migration, plus KEGG cancer/metabolic terms. These are useful contextual mappings, but no new enrichment P value or FDR was supplied.
- **Network evidence:** The batch reports 42 STRING edges. Examples include associations around CS, LRCH1/LRCH3 and DOCK-family proteins, ARG1/ARG2 with ASL/CRYM, and mitochondrial/metabolic genes. These records indicate database-supported relationships; they do not uniformly specify direct physical binding, and they do not prove causality.
- **Literature evidence:** The most relevant supplied records concern INHBB in colorectal cancer, CDX2 in colon cancer, NT5E/CD73 across cancers, and ATP23 biology. These sources support plausibility but may overlap with database annotations and are not independent statistical validation.
- **External statistical validation:** **External statistical validation was not performed.** No independent cohort, endpoint-specific HR, confidence interval, P value, FDR, or adjusted model was supplied. Therefore, the programs are not externally replicated or clinically validated.
- **Conflicts:** The immune-associated genes do not share one direction, and the metabolic and epithelial interpretations could be confounded by cellular composition. DCBLD2, RBMX-containing grouped records, and BCL2L14 have row-level direction conflicts and require probe-level resolution.

## 6. Major limitations and alternative explanations

1. **Tumor purity and cell composition:** Stromal or immune abundance could raise risk-associated extracellular-interface genes, while epithelial content could raise protective CDX1/CDX2, MYO5B, and LGALS4. Use purity estimates, single-cell references, deconvolution, and spatial protein assays to distinguish composition from tumor-cell-intrinsic biology.

2. **Clinical confounding:** Stage, metastasis, treatment exposure, age, sex, MSI status, and molecular subtype may explain part of the survival associations. Multivariable Cox models and stratified analyses are required.

3. **Probe duplication and annotation uncertainty:** Fifty-three genes/probe groups have duplicated rows, and some have direction conflicts. Re-map probes, inspect transcript-level measurements, and report probe-specific estimates before selecting therapeutic or mechanistic candidates.

4. **Absence of formal program-level statistics:** Recurrent GO/KEGG annotations and STRING edges do not establish enrichment. A prespecified gene-set analysis with effect-direction testing, permutation control, and pathway-level FDR should be performed using the full expression or survival-statistics matrix.

5. **Association-versus-causation ambiguity:** A prognostic HR may reflect a marker of tumor state, lineage, or treatment response rather than a driver. Functional perturbation, rescue experiments, and validation in an independent clinically annotated cohort are needed before causal or therapeutic claims.

Overall, the most defensible interpretation is a prognostic contrast between a risk-associated extracellular-interface/invasive state and a protective differentiated epithelial–mitochondrial state, with INHBB, ATP23, NDUFA9, CDX2, TPM4, ITGBL1, NT5E, and the metabolic module deserving prioritized validation while external statistical validation remains unavailable.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=111, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: OpenAI / gpt-5.6-luna

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 86/100 selected items (records returned); cbioportal 78/100 selected items (records returned); chembl 14/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 32/100 selected items (records returned); clinvar 83/100 selected items (records returned); ensembl 41/100 selected items (partially returned; some queries failed); europepmc 866 articles / initial full-cohort RAG 100 queries + 4 current-round queries; some queries failed; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 75/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 78/100 selected items (records returned); mygene 86/100 selected items (records returned); omnipath 32/100 selected items (records returned); opentargets 40/100 selected items (partially returned; some queries failed); pubmed 699 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 79/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 25/100 selected items (records returned); string 73/100 selected items (records returned); trrust 14/100 selected items (records returned)
